Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance (ELV) continues to focus on increasing shareholder value with consistent dividend payouts and stock repurchases.

Elevance (ELV) Rises 14.9% YTD: What Lies Ahead for Investors?

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health Foundation, the philanthropic arm of Elevance Health, today announces a $10 million commitment to launch a new impact investing program to create positive social impact through investment opportunities beyond its existing grant portfolio. The new program will provide loans to small businesses, social enterprises, and entrepreneurs that support health equity in under-resourced communities. Through loans with interest rates below Prime rates, these p.

Elevance Health Foundation Announces $10 Million to Launch New Impact Investing Initiative

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at Bernstein's 40th Annual Strategic Decisions Conference in New York City, on May 31 at 9:00 a.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the link here. For those unable to listen to the live webcast, a replay wil.

Elevance Health Announces Appearance at Bernstein's 40th Annual Strategic Decisions Conference

AbbVie

Ally Financial

Comcast

Camden Property

Cisco Systems

Discover

DHL Group

Dow Inc

First American Financial

MetLife

Merck

Nucor

Teleperformance

The April/May 2024 edition of Fortune Magazine revealed its 100 Best Companies To Work For, or Besties. My latest Dogcatcher-quest to sniff-out the best dividend-buys found 56 dividend-paying Besties using YCharts 5/13/24 data.

2 Fortune 100 Best Co's To Work For Are Also Good To Own

Apple

Alphabet

Microsoft

Amazon

Chevron

General Electric

UnitedHealth Group

Exxon Mobil

Giant S&P 500 companies keep tossing dividends and buybacks at investors. The reason is simple: They can't get rid of cash fast.

Ten Stocks Squat On 34% Of The S&P 500's Cash Pile

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is Elevance Health (ELV) a Buy as Wall Street Analysts Look Optimistic?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Elevance Health (ELV) is a Strong Momentum Stock

Elevance Health (ELV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Elevance Health (ELV) Rating Upgrade to Buy

Avantor Inc.

Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?

ELV or AVTR: Which Is the Better Value Stock Right Now?

Doximity

Medpace Holdings

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, MEDP and DOCS are set to gain the most.

3 Medical Services Industry Stocks to Buy as Nursing Market Booms

Cigna

Centene

Over the years, the healthcare industry in the United States has morphed into a complex web of insurance companies, hospital corporations and medical providers. Since the 2020 Coronavirus pandemic, U.S. healthcare spending and government subsidization have ballooned to nearly double pre-pandemic levels.

3 Healthcare Stocks to Buy Now: Q2 Edition

In the stock market, investor sentiment can change very quickly. Elevance Health's total revenue and adjusted diluted EPS climbed higher during the first quarter. The company's financial positioning is solid, which is supported by the interest coverage ratio.

Elevance Health: It's Not Too Late To Buy Their Dividend Growth

Aflac

Cummins

Corteva Inc

Dominion Energy

eBay

Con Ed

Emerson Electric

Fortune Brands Innovations Inc

FirstEnergy

W.W. Grainger

Intel

Johnson & Johnson

Nordstrom

Jackson Financial

KeyCorp

Kroger

LyondellBasell Industries

Main Street Capital

McDonald's

Pfizer

2023 was up 24%. 3 months down in 2024 and the S&P 500 is already up 6%, down from the plus 10% they were at.

Dividend Income Summary: Lanny's March 2024 Summary

Shares of Elevance Health (ELV) rose to their highest level since late 2022 on Thursday as the health insurance provider posted better-than-expected results and raised its guidance amid lower costs.

Elevance Health Stock Rises After Earnings Top Expectations, Guidance Boosted

Elevance Health Inc.'s stock rose 4.7% on Thursday, after the health insurer posted better-than-expected profit for the first quarter and raised a full-year guidance metric, offsetting a revenue shortfall.

Elevance Health's quarterly profit tops estimates to offset a revenue shortfall

Elevance Health (ELV) has a leftover capacity of around $3.6 billion under its share buyback authorization.

Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised

Elevance Health, Inc. (NYSE:ELV ) Q1 2024 Earnings Call Transcript April 18, 2024 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO Mark Kaye - CFO Peter Haytaian - President, Carelon Felicia Norwood - President, Government Health Benefits Business Conference Call Participants Lance Wilkes - Bernstein AJ Rice - UBS Josh Raskin - Nephron Research Ben Hendrix - RBC Capital Markets Dave Windley - Jefferies Lisa Gill - JPMorgan Kevin Fischbeck - Bank of America Whit Mayo - Leerink Partners Nathan Rich - Goldman Sachs Stephen Baxter - Wells Fargo Andrew Mok - Barclays George Hill - Deutsche Bank Scott Fidel - Stephens Justin Lake - Wolfe Research Ann Hynes - Mizuho Gary Taylor - TD Cowen Sarah James - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by and welcome to the Elevance Health First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

Elevance Health, Inc. (ELV) Q1 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Elevance Health (ELV) Q1 Earnings: A Look at Key Metrics

Elevance Health (ELV) came out with quarterly earnings of $10.64 per share, beating the Zacks Consensus Estimate of $10.54 per share. This compares to earnings of $9.46 per share a year ago.

Elevance Health (ELV) Beats Q1 Earnings Estimates

Elevance Health beat Wall Street estimates for first-quarter profit on Thursday, as higher premiums in its commercial insurance business helped keep medical costs for the insurer in check.

Elevance beats first-quarter profit estimates on higher premiums

INDIANAPOLIS--(BUSINESS WIRE)---- $ELV #earnings--Elevance Health, Inc. (NYSE: ELV) reported first quarter 2024 results. “First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry. We are making significant progress expanding Carelon's capabilities, scaling our flywheel for enterprise growth, and delivering results for all stakeholders. Given the solid start to the year, we have increased our outlook for full year earnings. Earlier this week, we also a.

Elevance Health Reports First Quarter 2024 Results

Elevance (ELV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Elevance (ELV) This Earnings Season?

News for Elevance Health Inc Stock (ELV)